Search Results - "Bournia, V."

Treatment modalities and drug survival in a systemic sclerosis real-life patient cohort by Panopoulos, S, Chatzidionysiou, Κ, Tektonidou, M G, Bournia, V K, Drosos, A A, Liossis, Stamatis-Nick C, Dimitroulas, T, Sakkas, L, Boumpas, D, Voulgari, P V, Daoussis, D, Thomas, K, Georgiopoulos, G, Vosvotekas, G, Garyfallos, Α, Sidiropoulos, P, Bertsias, G, Vassilopoulos, D, Sfikakis, P P

“…European data indicate that systemic sclerosis (SSc)-related death rates are increasing, thus raising concerns about SSc's optimal management. Herein, we…”
Get full text

Outcomes of conventionally-treated systemic sclerosis patients eligible for autologous haematopoietic stem cell transplantation by Panopoulos, Stylianos T, Tektonidou, Maria G, Bournia, Vasiliki-Kalliopi, Laskari, Katerina, Sfikakis, Petros P

“…Autologous haematopoietic stem cell transplantation (HSCT) has exhibited superior efficacy compared to conventional immunosuppressives in rapidly progressive…”
Get more information

Absence of radiographic progression of hip arthritis during infliximab treatment for ankylosing spondylitis by Konsta, M., Sfikakis, P. P., Bournia, V. K., Karras, D., Iliopoulos, A.

“…This study aims to examine the impact of long-term treatment with the anti-TNF antibody infliximab on radiographic progression of hip arthritis in ankylosing…”
Get full text

Detection of coronary artery lesions and myocardial necrosis by magnetic resonance in systemic necrotizing vasculitides by Mavrogeni, S., Manoussakis, M. N., Karagiorga, T. C., Douskou, M., Panagiotakos, D., Bournia, V., Cokkinos, D. V., Moutsopoulos, H. M.

“…Objective Myocardium and coronary arteries can occasionally be affected in patients with systemic necrotizing vasculitides; however, such involvement has not…”
Get full text

H1N1 influenza outcome in rheumatic patients under biological therapy by BOURNIA, V. K, SFONTOURIS, C, KONSTA, M, ILIOPOULOS, A

Get full text

Adverse events and infections in patients with rheumatoid arthritis treated with conventional drugs or biologic agents: a real world study by Lampropoulos, Christos E, Orfanos, Philippos, Bournia, Vasiliki-Kalliopi, Karatsourakis, Theofilos, Mavragani, Clio, Pikazis, Dimitrios, Manoussakis, Menelaos N, Tzioufas, Athanasios G, Moutsopoulos, Haralampos M, Vlachoyiannopoulos, Panayiotis G

“…Treatment of rheumatoid arthritis (RA) with disease-modifying anti-rheumatic drugs (DMARDs), either synthetic (sDMARDs) or biologic agents (bDMARDs) has…”
Get full text

Do non-steroidal anti-inflammatory drugs increase or decrease cardiovascular risk in patients with rheumatoid arthritis? by Sfikakis, P P, Bournia, V-K, Kitas, G

Get full text

Mechanics of early ventricular impairment in systemic sclerosis and the effects of peripheral arterial haemodynamics by Tountas, Christos, Protogerou, Athanase D, Bournia, Vasiliki-Kalliopi, Panopoulos, Stylianos, Konstantonis, George, Tektonidou, Maria G, Gournizakis, Aristides, Beldekos, Dimitrios, Sfikakis, Petros P

“…OBJECTIVESMultiple mechanisms commonly lead to severe cardiac involvement in systemic sclerosis (SSc), an autoimmune disease characterised by microvascular…”
Get full text

Biologic treatment for rheumatic disease: real-world big data analysis from the Greek country-wide prescription database by Sfikakis, Petros P, Bournia, Vasiliki-Kalliopi, Sidiropoulos, Prodromos, Boumpas, Dimitrios T, Drosos, Alexandros A, Kitas, George D, Konstantonis, George, Liossis, Stamatis N, Manoussakis, Menelaos N, Sakkas, Lazaros, Tektonidou, Maria, Tzioufas, Athanasios G, Vlachoyiannopoulos, Panayiotis G, Kani, Chara, Paterakis, Panayiotis, Litsa, Panayiota, Vassilopoulos, Dimitrios

“…To directly assess the prevalence of inflammatory rheumatic disease under treatment with biologic disease modifying anti-rheumatic drugs (b-DMARDs) and compare…”
Get full text

Increased messenger RNA levels of the mesenchymal cadherin-11 in the peripheral blood of systemic sclerosis patients correlate with diffuse skin involvement by Christopoulos, Panagiotis F, Bournia, Vasiliki-Kalliopi, Panopoulos, Stylianos, Vaiopoulos, Aristeides, Koutsilieris, Michael, Sfikakis, Petros P

“…Cadherin-11 is a cell-cell adhesion molecule also involved in cellular migration and invasion. Experimental studies implicated this molecule in inflammatory…”
Get full text

Severe oesophageal disease and its associations with systemic sclerosis by Karamanolis, Georgios P, Denaxas, Konstantinos, Panopoulos, Stylianos, Bournia, Kalliopi-Vasiliki, Zorbala, Alexandra, Kamberoglou, Dimitrios, Schizas, Dimitrios, Ladas, Spiros D, Sfikakis, Petros P

“…Severe oesophageal disease in patients with systemic sclerosis (SSc), referred as scleroderma oesophagus, is characterised by ineffective or absent peristalsis…”
Get full text

Therapeutic Inhibition of Tyrosine Kinases in Systemic Sclerosis: A Review of Published Experience on the First 108 Patients Treated with Imatinib by Bournia, Vasiliki-Kalliopi, MD, Evangelou, Konstantinos, MD, PhD, Sfikakis, Petros P., MD

“…Objective Experimental and clinical evidence suggest a therapeutic role for the tyrosine kinase inhibitor imatinib in fibrosing conditions. We evaluated…”
Get full text

Mycophenolate Versus Cyclophosphamide for Progressive Interstitial Lung Disease Associated with Systemic Sclerosis: A 2-Year Case Control Study by Panopoulos, Stylianos T., Bournia, Vassiliki-Kalliopi, Trakada, Georgia, Giavri, Irene, Kostopoulos, Charalambos, Sfikakis, Petros P.

“…Objective Cyclophosphamide is considered the treatment of choice for interstitial lung disease (ILD) secondary to systemic sclerosis (SSc), albeit having a…”
Get full text

Atrial Fibrillation Following Intravenous Zolendronic Acid for Osteoporosis by Konsta, Maria, Bournia, Vasiliki-Kalliopi, Dania, Vasiliki, Iliopoulos, Alexios

Get full text